Home  |  Contact

Cellosaurus LNCaP C4-2B (CVCL_4784)

[Text version]

Cell line name LNCaP C4-2B
Synonyms C4-2B; C4-2 B; C4-2 Bone metastatic
Accession CVCL_4784
Resource Identification Initiative To cite this cell line use: LNCaP C4-2B (RRID:CVCL_4784)
Comments Characteristics: Bone metastatic.
Doubling time: 24-36 hours (ATCC).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Sequence variations Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
Disease Prostate carcinoma (NCIt: C4863)
Derived from metastatic site: Left supraclavicular lymph node.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_4782 (LNCaP C4-2)
Children:
CVCL_4785 (LNCaP C4-2B2)CVCL_4786 (LNCaP C4-2B3)CVCL_4787 (LNCaP C4-2B4)
CVCL_4788 (LNCaP C4-2B5)
Sex of cell Male
Age at sampling 50Y
Category Cancer cell line
STR profile Source(s): ATCC

Markers:
AmelogeninX,Y
CSF1PO9,10,11
D5S81811,12
D7S8208.1,9.1,10.3
D13S31710,11
D16S53910,11
TH019
TPOX8,9
vWA16,18

Run an STR similarity search on this cell line
Web pages https://en.wikipedia.org/wiki/LNCaP
Publications

PubMed=8168083
Thalmann G.N., Anezinis P.E., Chang S.-M., Zhau H.E., Kim E.E., Hopwood V.L., Pathak S., von Eschenbach A.C., Chung L.W.K.
Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.
Cancer Res. 54:2577-2581(1994)

PubMed=15162376; DOI=10.1002/pros.20031
Liu A.Y., Brubaker K.D., Goo Y.A., Quinn J.E., Kral S., Sorensen C.M., Vessella R.L., Belldegrun A.S., Hood L.E.
Lineage relationship between LNCaP and LNCaP-derived prostate cancer cell lines.
Prostate 60:98-108(2004)

PubMed=24587179; DOI=10.1371/journal.pone.0090002
Spans L., Helsen C., Clinckemalie L., Van den Broeck T., Prekovic S., Joniau S., Lerut E., Claessens F.
Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines.
PLoS ONE 9:E90002-E90002(2014)

PubMed=33298586; DOI=10.1158/1535-7163.MCT-20-0244
Kohrt S.E., Awadallah W.N., Phillips R.A. III, Case T.C., Jin R.-J., Nanda J.S., Yu X.-P., Clark P.E., Yi Y.-J., Matusik R.J., Anderson P.D., Grabowska M.M.
Identification of genes required for enzalutamide resistance in castration-resistant prostate cancer cells in vitro.
Mol. Cancer Ther. 20:398-409(2021)

Cross-references
Cell line collections ATCC; CRL-3315
Ontologies BTO; BTO:0004959
EFO; EFO_0006365
Biological sample resources ENCODE; ENCBS002MOV
ENCODE; ENCBS108UKE
ENCODE; ENCBS109FVF
ENCODE; ENCBS159HRH
ENCODE; ENCBS328CYG
ENCODE; ENCBS391IVJ
ENCODE; ENCBS440KYC
ENCODE; ENCBS582KTC
ENCODE; ENCBS728XMM
ENCODE; ENCBS947VNK
Gene expression databases GEO; GSM648816
Other Wikidata; Q54902815
Polymorphism and mutation databases Cosmic; 1689709
Progenetix; CVCL_4784
Entry history
Entry creation04-Apr-2012
Last entry update20-May-2021
Version number22